Calcimimetic agents, such as cinacalcet, which act on the calcium-sensing receptor (CaSR) responsible for regulation and hemostasis of calcium through actions on the parathyroid gland and kidney [29], are effective in reducing serum calcium levels by at least 1 mg/dl in 62% of patients with PC [9]. The gene discussed is CASR; the disease is pachyonychia congenita.